Annual report
2370.TEDINET S100XB0H
Period2024-10-01 → 2025-09-30
Filed2025-12-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 83
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥810m | 2024-10-01 → 2025-09-30 | Standalone | Net sales |
| Revenue | ¥769m | 2023-10-01 → 2024-09-30 | Standalone | Net sales |
| Revenue | ¥662m | 2022-10-01 → 2023-09-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥634m | 2021-10-01 → 2022-09-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥683m | 2020-10-01 → 2021-09-30d | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.4bn | 2024-10-01 → 2025-09-30 | Standalone | Operating income |
| Operating income | −¥1.4bn | 2023-10-01 → 2024-09-30 | Standalone | Operating income |
| Ordinary income | −¥1.3bn | 2024-10-01 → 2025-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.4bn | 2022-10-01 → 2023-09-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.3bn | 2021-10-01 → 2022-09-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥871m | 2020-10-01 → 2021-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.4bn | 2024-10-01 → 2025-09-30 | Standalone | Income before income taxes |
| Profit before tax | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Income before income taxes |
| Net income | −¥1.4bn | 2024-10-01 → 2025-09-30 | Standalone | Profit loss |
| Net income | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Profit loss |
| Net income | −¥1.4bn | 2022-10-01 → 2023-09-30v | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.3bn | 2021-10-01 → 2022-09-30v | Standalone | Net income loss (5-year summary) |
| Net income | −¥843m | 2020-10-01 → 2021-09-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥4.3bn | at 2025-09-30 | Standalone | Assets |
| Total assets | ¥5.7bn | at 2024-09-30 | Standalone | Assets |
| Total assets | ¥5.6bn | at 2023-09-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.1bn | at 2022-09-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥5.4bn | at 2021-09-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥476m | at 2025-09-30 | Standalone | Liabilities |
| Total liabilities | ¥509m | at 2024-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥3.8bn | at 2025-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.2bn | at 2024-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.0bn | at 2023-09-30v | Standalone | Net assets |
| Net assets / equity | ¥5.5bn | at 2022-09-30v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.9bn | at 2021-09-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2025-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.7bn | at 2024-09-30 | Standalone | Cash and deposits |
| Cash & equivalents | ¥2.7bn | at 2025-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2024-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.4bn | at 2023-09-30v | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2022-09-30v | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.1bn | at 2021-09-30d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.4bn | 2024-10-01 → 2025-09-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.3bn | 2022-10-01 → 2023-09-30v | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.2bn | 2021-10-01 → 2022-09-30v | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥975m | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥565m | 2024-10-01 → 2025-09-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥65m | 2023-10-01 → 2024-09-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥3m | 2022-10-01 → 2023-09-30v | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥20m | 2021-10-01 → 2022-09-30v | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥344m | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥3m | 2024-10-01 → 2025-09-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2023-10-01 → 2024-09-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.2bn | 2022-10-01 → 2023-09-30v | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.6bn | 2021-10-01 → 2022-09-30v | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-5.15 | 2024-10-01 → 2025-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.04 | 2023-10-01 → 2024-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.65 | 2022-10-01 → 2023-09-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.33 | 2021-10-01 → 2022-09-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.88 | 2020-10-01 → 2021-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥14.27 | at 2025-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥19.62 | at 2024-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥21.64 | at 2023-09-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥26.03 | at 2022-09-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥27.31 | at 2021-09-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 88.8% | at 2025-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.1% | at 2024-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.2% | at 2023-09-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.7% | at 2022-09-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.8% | at 2021-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -30.4% | 2024-10-01 → 2025-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -25.0% | 2023-10-01 → 2024-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -27.3% | 2022-10-01 → 2023-09-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | -24.1% | 2021-10-01 → 2022-09-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | -17.5% | 2020-10-01 → 2021-09-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 264,729,198 | at 2025-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 264,515,306 | at 2024-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 232,160,757 | at 2023-09-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 211,730,423 | at 2022-09-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 178,750,423 | at 2021-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 107 | at 2025-09-30 | Standalone | Number of employees |
| Employees | 112 | at 2024-09-30 | Standalone | Number of employees |
| Employees | 98 | at 2023-09-30v | Standalone | Number of employees |
| Employees | 96 | at 2022-09-30v | Standalone | Number of employees |
| Employees | 83 | at 2021-09-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-10-01 → 2025-09-30 | ¥4m |
| Reconciling Itemsreconciling | depreciation | 2024-10-01 → 2025-09-30 | ¥15m |
| Reconciling Itemsreconciling | segment assets | at 2025-09-30 | ¥3.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-10-01 → 2025-09-30 | −¥563m |
| Cellular And Tissue Based Product Businessreportable segment | capex | 2024-10-01 → 2025-09-30 | ¥3m |
| Cellular And Tissue Based Product Businessreportable segment | depreciation | 2024-10-01 → 2025-09-30 | ¥22m |
| Cellular And Tissue Based Product Businessreportable segment | employees | at 2025-09-30 | 16 pure |
| Cellular And Tissue Based Product Businessreportable segment | revenue | 2024-10-01 → 2025-09-30 | ¥219,000 |
| Cellular And Tissue Based Product Businessreportable segment | revenue external | 2024-10-01 → 2025-09-30 | ¥219,000 |
| Cellular And Tissue Based Product Businessreportable segment | segment assets | at 2025-09-30 | ¥139m |
| Cellular And Tissue Based Product Businessreportable segment | segment profit | 2024-10-01 → 2025-09-30 | −¥408m |
| Contracted Cell Manufacturing Businessreportable segment | capex | 2024-10-01 → 2025-09-30 | ¥20m |
| Contracted Cell Manufacturing Businessreportable segment | depreciation | 2024-10-01 → 2025-09-30 | ¥64m |
| Contracted Cell Manufacturing Businessreportable segment | employees | at 2025-09-30 | 78 pure |
| Contracted Cell Manufacturing Businessreportable segment | revenue | 2024-10-01 → 2025-09-30 | ¥810m |
| Contracted Cell Manufacturing Businessreportable segment | revenue external | 2024-10-01 → 2025-09-30 | ¥810m |
| Contracted Cell Manufacturing Businessreportable segment | segment assets | at 2025-09-30 | ¥687m |
| Contracted Cell Manufacturing Businessreportable segment | segment profit | 2024-10-01 → 2025-09-30 | −¥475m |
| —segment total | capex | 2024-10-01 → 2025-09-30 | ¥24m |
| —segment total | depreciation | 2024-10-01 → 2025-09-30 | ¥86m |
| —segment total | revenue | 2024-10-01 → 2025-09-30 | ¥810m |
| —segment total | revenue external | 2024-10-01 → 2025-09-30 | ¥810m |
| —segment total | segment assets | at 2025-09-30 | ¥826m |
| —segment total | segment profit | 2024-10-01 → 2025-09-30 | −¥883m |
| Reconciling Itemsreconciling | capex | 2023-10-01 → 2024-09-30 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2023-10-01 → 2024-09-30 | ¥18m |
| Reconciling Itemsreconciling | segment assets | at 2024-09-30 | ¥4.9bn |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-09-30 | −¥577m |
| Cellular And Tissue Based Product Businessreportable segment | capex | 2023-10-01 → 2024-09-30 | ¥21m |
| Cellular And Tissue Based Product Businessreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥36m |
| Cellular And Tissue Based Product Businessreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥245,000 |
| Cellular And Tissue Based Product Businessreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥245,000 |
| Cellular And Tissue Based Product Businessreportable segment | segment assets | at 2024-09-30 | ¥116m |
| Cellular And Tissue Based Product Businessreportable segment | segment profit | 2023-10-01 → 2024-09-30 | −¥435m |
| Contracted Cell Manufacturing Businessreportable segment | capex | 2023-10-01 → 2024-09-30 | ¥23m |
| Contracted Cell Manufacturing Businessreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥61m |
| Contracted Cell Manufacturing Businessreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥768m |
| Contracted Cell Manufacturing Businessreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥768m |
| Contracted Cell Manufacturing Businessreportable segment | segment assets | at 2024-09-30 | ¥667m |
| Contracted Cell Manufacturing Businessreportable segment | segment profit | 2023-10-01 → 2024-09-30 | −¥374m |
| —segment total | capex | 2023-10-01 → 2024-09-30 | ¥44m |
| —segment total | depreciation | 2023-10-01 → 2024-09-30 | ¥97m |
| —segment total | revenue | 2023-10-01 → 2024-09-30 | ¥769m |
| —segment total | revenue external | 2023-10-01 → 2024-09-30 | ¥769m |
| —segment total | segment assets | at 2024-09-30 | ¥783m |
| —segment total | segment profit | 2023-10-01 → 2024-09-30 | −¥808m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 961
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)普 賢 監 査 法 人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)佐藤 功一 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)髙橋 弘 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)継続企業の前提に関する重要な不確実性の有無についての経営者による判断 | |
| Description including reason kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Auditors response kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 683033000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 633672000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 661543000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 768501000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 810291000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration_NonConsolidatedMember | -870726000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration_NonConsolidatedMember | -1314262000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration_NonConsolidatedMember | -1419182000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration_NonConsolidatedMember | -1261583000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration_NonConsolidatedMember | -1339843000 | JPY |
| Net income loss (5-year summary) | Prior4YearDuration_NonConsolidatedMember | -843396000 | JPY |
| Net income loss (5-year summary) | Prior3YearDuration_NonConsolidatedMember | -1254092000 | JPY |
| Net income loss (5-year summary) | Prior2YearDuration_NonConsolidatedMember | -1437950000 | JPY |
| Net income loss (5-year summary) | Prior1YearDuration_NonConsolidatedMember | -1276994000 | JPY |
| Net income loss (5-year summary) | CurrentYearDuration_NonConsolidatedMember | -1362138000 | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior4YearDuration_NonConsolidatedMember | － | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior3YearDuration_NonConsolidatedMember | － | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior2YearDuration_NonConsolidatedMember | － | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior1YearDuration_NonConsolidatedMember | － | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | CurrentYearDuration_NonConsolidatedMember | － | JPY |
| Capital stock (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 5082073000 | JPY |
| Capital stock (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 5892020000 | JPY |
| Capital stock (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 5736788000 | JPY |
| Capital stock (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 6486162000 | JPY |
| Capital stock (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 5102250000 | JPY |
| Total number of issued shares (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 178750423 | |
| Total number of issued shares (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 211730423 | |
| Total number of issued shares (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 232160757 | |
| Total number of issued shares (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 264515306 | |
| Total number of issued shares (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 264729198 | |
| Net assets (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 4902726000 | JPY |
| Net assets (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 5511924000 | JPY |
| Net assets (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 5043941000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 5190766000 | JPY |
| Net assets (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 3777572000 | JPY |
| Total assets (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 5377672000 | JPY |
| Total assets (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 6078061000 | JPY |
| Total assets (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 5634145000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |